GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Revenue

Changzhou Qianhong Biopharma Co (SZSE:002550) Revenue : ¥1,556 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Revenue?

Changzhou Qianhong Biopharma Co's revenue for the three months ended in Sep. 2024 was ¥352 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ¥1,556 Mil. Changzhou Qianhong Biopharma Co's Revenue per Share for the three months ended in Sep. 2024 was ¥0.28. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ¥1.22.

Warning Sign:

Changzhou Qianhong Biopharma Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Changzhou Qianhong Biopharma Co was -24.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 0.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Changzhou Qianhong Biopharma Co's highest 3-Year average Revenue per Share Growth Rate was 58.70% per year. The lowest was -17.50% per year. And the median was 7.95% per year.


Changzhou Qianhong Biopharma Co Revenue Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Revenue Chart

Changzhou Qianhong Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,675.15 1,667.61 1,874.94 2,303.55 1,814.27

Changzhou Qianhong Biopharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 409.19 348.33 461.10 394.49 352.01

Competitive Comparison of Changzhou Qianhong Biopharma Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changzhou Qianhong Biopharma Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Revenue distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Revenue falls into.


;
;

Changzhou Qianhong Biopharma Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,556 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Changzhou Qianhong Biopharma Co  (SZSE:002550) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Changzhou Qianhong Biopharma Co Revenue Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
Executives
Huang Jie Executives
Wang Ke Directors, executives
Jiang Wen Qun Supervisors
Zou Shao Bo Executives
Wei Li Jun Executives
Mei Chun Wei Executives
Zhou Xiang Directors, executives
Zhao Gang Director
Ye Hong Ping Executives
Liu Jun Director
Fan Yong Executives
Jiang Jian Ping Supervisors
Wang Yao Fang Director
Hai Tao Directors, executives
Wang Yi Director

Changzhou Qianhong Biopharma Co Headlines

No Headlines